Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Recurrent Epithelial Ovarian, Fallopian or Peritoneal Carcinoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Active Not RecruitingNCT02627443
What this trial is testing

Carboplatin, Gemcitabine Hydrochloride, and Berzosertib in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Who this might be right for
Metastatic Fallopian Tube CarcinomaMetastatic Ovarian CarcinomaMetastatic Primary Peritoneal Carcinoma+9 more
National Cancer Institute (NCI) 35
Testing effectiveness (Phase 2)Study completedNCT03093155
What this trial is testing

Evaluation of Weekly Ixabepilone With or Without Biweekly Bevacizumab

Who this might be right for
Epithelial Ovarian CancerFallopian Tube CancerPrimary Peritoneal Cancer
Yale University 78
Testing effectiveness (Phase 2)Study completedNCT00072267
What this trial is testing

UCN-01 and Topotecan in Treating Patients With Recurrent, Persistent, or Progressive Advanced Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

Who this might be right for
Fallopian Tube CancerOvarian CancerPrimary Peritoneal Cavity Cancer
University Health Network, Toronto
Testing effectiveness (Phase 2)Study completedNCT00499252
What this trial is testing

Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Who this might be right for
Fallopian Tube CarcinomaPrimary Peritoneal CarcinomaRecurrent Ovarian Carcinoma
Gynecologic Oncology Group 51
Testing effectiveness (Phase 2)Study completedNCT00617773
What this trial is testing

Hu3S193 in Treating Women With Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

Who this might be right for
Fallopian Tube CancerOvarian CancerPrimary Peritoneal Cancer
Recepta Biopharma 31
Testing effectiveness (Phase 2)UnknownNCT00003064
What this trial is testing

Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Persistent Epithelial Ovarian Cancer, Fallopian Tube, or Primary Peritoneal Cancer

Who this might be right for
Fallopian Tube CancerOvarian CancerPrimary Peritoneal Cavity Cancer
Herbert Irving Comprehensive Cancer Center 30
Testing effectiveness (Phase 2)Study completedNCT02498600
What this trial is testing

Nivolumab With or Without Ipilimumab in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Who this might be right for
Recurrent Fallopian Tube CarcinomaRecurrent Ovarian CarcinomaRecurrent Primary Peritoneal Carcinoma
National Cancer Institute (NCI) 100
Testing effectiveness (Phase 2)Study completedNCT00017017
What this trial is testing

CT-2103 in Treating Patients With Recurrent Ovarian Epithelial or Fallopian Tube Cancer or Primary Peritoneal Cancer

Who this might be right for
Fallopian Tube CancerOvarian CancerPrimary Peritoneal Cavity Cancer
Memorial Sloan Kettering Cancer Center
Testing effectiveness (Phase 2)UnknownNCT00305838
What this trial is testing

CA 125 Levels in Treating Patients With Relapsed Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Who Are Receiving Tamoxifen

Who this might be right for
Fallopian Tube CancerOvarian CancerPrimary Peritoneal Cavity Cancer
Mount Vernon Cancer Centre at Mount Vernon Hospital 200
Early research (Phase 1)WithdrawnNCT02627430
What this trial is testing

Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced Solid Tumor or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple Negative Breast Cancer

Who this might be right for
Adult Solid NeoplasmEstrogen Receptor NegativeFallopian Tube Serous Neoplasm+10 more
National Cancer Institute (NCI)
Early research (Phase 1)Study completedNCT02046421
What this trial is testing

Carboplatin, Gemcitabine Hydrochloride, and Mifepristone in Treating Patients With Advanced Breast Cancer or Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

Who this might be right for
Male Breast CancerRecurrent Breast CancerRecurrent Fallopian Tube Cancer+5 more
University of Chicago 31
Testing effectiveness (Phase 2)Looking for participantsNCT07589543
What this trial is testing

Dual-Target CAR-NK Cells in Recurrent or Refractory Epithelial Ovarian Cancer

Who this might be right for
Epithelial Ovarian CancerEpithelial Ovarian Cancer, Fallopian Tube or Peritoneum
Beijing Biotech 42
Testing effectiveness (Phase 2)Study completedNCT00301756
What this trial is testing

Belinostat in Treating Patients With Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer or Ovarian Low Malignant Potential Tumors

Who this might be right for
Fallopian Tube CarcinomaPrimary Peritoneal CarcinomaRecurrent Borderline Ovarian Surface Epithelial-Stromal Tumor+5 more
National Cancer Institute (NCI) 32
Early research (Phase 1)Study completedNCT03732768
What this trial is testing

Study of Radspherin® in Recurrent Ovarian Cancer Subjects With Peritoneal Carcinomatosis

Who this might be right for
Peritoneal CarcinomatosisOvarian Cancer
Oncoinvent Solutions AS 21
Not applicableWithdrawnNCT00551265
What this trial is testing

Oregovomab With or Without Cyclophosphamide in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Responded to Second-Line Chemotherapy

Who this might be right for
Fallopian Tube CarcinomaPrimary Peritoneal CarcinomaRecurrent Ovarian Carcinoma+2 more
Gynecologic Oncology Group
Testing effectiveness (Phase 2)Active Not RecruitingNCT03673124
What this trial is testing

Ribociclib and Letrozole Treatment in Ovarian Cancer

Who this might be right for
Low Grade Serous Carcinoma
Gynecologic Oncology Group 51
Testing effectiveness (Phase 2)Study completedNCT00886691
What this trial is testing

Bevacizumab With or Without Everolimus in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Who this might be right for
Recurrent Fallopian Tube CarcinomaRecurrent Ovarian CarcinomaRecurrent Primary Peritoneal Carcinoma
GOG Foundation 150
Testing effectiveness (Phase 2)UnknownNCT02188550
What this trial is testing

Single Arm Trial With Combination of Everolimus and Letrozole in Treatment of Platinum Resistant Relapse or Refractory or Persistent Ovarian Cancer/Endometrial Cancer

Who this might be right for
Ovarian CancerEndometrial Cancer
Sinai Hospital of Baltimore 20
Testing effectiveness (Phase 2)Study completedNCT01010126
What this trial is testing

Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer

Who this might be right for
Adult Hepatocellular CarcinomaAdvanced Adult Hepatocellular CarcinomaEndometrial Serous Adenocarcinoma+42 more
National Cancer Institute (NCI) 252
Early research (Phase 1)Study completedNCT01074411
What this trial is testing

Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Who this might be right for
Fallopian Tube Clear Cell AdenocarcinomaFallopian Tube Endometrioid AdenocarcinomaFallopian Tube Mucinous Adenocarcinoma+17 more
National Cancer Institute (NCI) 33
Next Page